|
|
Patients With HER2-Positive Breast Cancer Significantly Benefit From Addition of Xeloda to Herceptin and Taxotere Therapy.
- Article from:
-
PR Newswire Europe
- Article date:
-
October 2, 2006
|
Copyright informationCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ISTANBUL, Turkey, October 2 /PRNewswire/ --
- New combination provides effective option for women with advanced stage of aggressive breast cancer
- Embargoed until 14.45 EEST (GMT + 2) 2 October, 2006
New data presented today at the European Society for Medical Oncology (ESMO) show that the addition of Xeloda (capecitabine) to the combination of Herceptin (trastuzumab) and Taxotere (docetaxel) significantly increases the amount of time patients with HER2-positive advanced breast cancer have without their disease progressing. The median time to progression increased significantly from 13.8 to 18.2 months (p-value = 0.045).
HER2-positive breast cancer, which ...